Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeuroSense Therapeutics Ltd. - Ordinary Shares (NQ:NRSN)

0.5300 +0.0100 (+1.92%)
Streaming Delayed Price Updated: 10:44 AM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 169,242
Open 0.5100
Bid (Size) 0.5200 (17,700)
Ask (Size) 0.5490 (500)
Prev. Close 0.5200
Today's Range 0.5100 - 0.6000
52wk Range 0.3930 - 1.980
Shares Outstanding 23,228,941
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which stocks are moving after the closing bell on Wednesday? ↗
Via Chartmill
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions

Performance

YTD
-32.0%
-32.0%
1 Month
-23.9%
-23.9%
3 Month
-44.2%
-44.2%
6 Month
-42.4%
-42.4%
1 Year
-57.9%
-57.9%

More News

Read More
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Wednesday's session: top gainers and losers ↗
Via Chartmill
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads
Via News Direct
Topics Regulatory Compliance
News headline image
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights ↗
Via Benzinga
News headline image
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday ↗
Via Benzinga
News headline image
NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement
Via News Direct
News headline image
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
From Market News Alerts
Via Business Wire
News headline image
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
Via News Direct
Topics Regulatory Compliance
News headline image
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
From PESG Research
Via Business Wire
News headline image
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission ↗
Via Benzinga
News headline image
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market
Via News Direct
News headline image
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug ↗
Via Benzinga
News headline image
NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024 ↗
Via InvestorPlace
News headline image
NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023 ↗
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Via InvestorPlace
News headline image
NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 ↗
Via Benzinga
News headline image
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Via Benzinga
News headline image
US Stocks Higher; Private Payrolls Rise By 103,000 In November ↗
Via Benzinga
Topics Stocks
News headline image
Why SentinelOne Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Via InvestorPlace

Frequently Asked Questions

Is NeuroSense Therapeutics Ltd. - Ordinary Shares publicly traded?
Yes, NeuroSense Therapeutics Ltd. - Ordinary Shares is publicly traded.
What exchange does NeuroSense Therapeutics Ltd. - Ordinary Shares trade on?
NeuroSense Therapeutics Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NeuroSense Therapeutics Ltd. - Ordinary Shares?
The ticker symbol for NeuroSense Therapeutics Ltd. - Ordinary Shares is NRSN on the Nasdaq Stock Market
What is the current price of NeuroSense Therapeutics Ltd. - Ordinary Shares?
The current price of NeuroSense Therapeutics Ltd. - Ordinary Shares is 0.5300
When was NeuroSense Therapeutics Ltd. - Ordinary Shares last traded?
The last trade of NeuroSense Therapeutics Ltd. - Ordinary Shares was at 08/05/26 10:44 AM ET
What is the market capitalization of NeuroSense Therapeutics Ltd. - Ordinary Shares?
The market capitalization of NeuroSense Therapeutics Ltd. - Ordinary Shares is 12.31M
How many shares of NeuroSense Therapeutics Ltd. - Ordinary Shares are outstanding?
NeuroSense Therapeutics Ltd. - Ordinary Shares has 12M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback